{"filings":[{"id":2051356,"accession_number":"0000882095-26-000028","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2026-08-04T20:03:26+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gilead Q2 2026 Revenue Up 10% to $7.8B; Diluted Loss Per Share $(8.45) on $11.2B IPR&D Charges","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q2 2026 revenues increased 10% to $7.8 billion compared to Q2 2025.","Product sales excluding Veklury increased 10% to $7.6 billion, driven by HIV portfolio, Trodelvy, and Livdelzi.","Diluted loss per share was $(8.45) due to $11.2 billion in acquired IPR&D expenses from Arcellx, Tubulis, and Ouro Medicines acquisitions.","Biktarvy sales increased 7% to $3.8 billion; Descovy sales up 48% to $967 million.","Gilead updated 2026 guidance: product sales ex-Veklury now $29.8B-$30.1B, up from prior $29.4B-$29.8B."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":554721,"accession_number":"0001104659-26-064518","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2026-05-20T20:15:36+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Gilead Sciences issues $3.0B in senior notes across four tranches (4.250%-4.900%)","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$500M 4.250% Senior Notes due 2028, $1B 4.400% due 2029, $1B 4.600% due 2031, $500M 4.900% due 2034.","Notes sold in public offering under Form S-3 shelf; proceeds for general corporate purposes incl. M&A.","Underwriting agreement dated May 14, 2026, with Barclays, BofA Securities, and Citigroup as reps."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99392,"accession_number":"0000882095-26-000022","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gilead Q1 rev $7.0B (+4% YoY); raises FY rev guidance but slashes EPS guidance due to $11.5B charges","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product sales ex-Veklury $6.8B (+8% YoY); HIV sales $5.0B (+10%); Biktarvy $3.4B (+7%).","GAAP diluted EPS $1.61 (vs $1.04); non-GAAP $2.03 (vs $1.81) — both up YoY.","Full-year product sales guidance raised to $30.0-30.4B; GAAP EPS guidance cut to $(3.25)-(2.85) from $6.75-7.15.","EPS guidance reduction driven by anticipated $11.5B IPR&D charges for Arcellx, Ouro and Tubulis acquisitions.","Cell Therapy sales down 12% to $407M; Trodelvy up 37% to $402M; Veklury down 52% to $144M."],"consensus_eps_estimate":null,"consensus_eps_actual":1.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":6960000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99391,"accession_number":"0000882095-26-000008","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Gilead shareholders elect all nine directors, approve equity plan increase, reject three proposals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected; Daniel O'Day received 980.6M votes for, 50.2M against.","Ernst & Young ratified as auditor for FY 2026: 1,046.4M for, 82.8M against, 1.0M abstain.","Say-on-pay approved with 954.3M for (92.6% of votes cast excluding broker non-votes).","Amended 2022 Equity Incentive Plan approved, adding 47.75M new shares to the pool.","Shareholder proposals on independent chair, patent exclusivity, and ESG metrics all defeated by wide margins."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99390,"accession_number":"0001104659-26-049874","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["7.01","9.01","8.01"],"status":"ready","headline":"Gilead completes $7.8B acquisition of Arcellx; adds anito-cel CAR T therapy for multiple myeloma","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price $115/share cash plus $5 CVR (contingent on $6B anito-cel sales by end-2029); total implied equity ~$7.8B.","Tender offer accepted 38.8M shares (~77.2% of outstanding); merger completed April 28, 2026.","Expected EPS dilution of ~$5.57-$5.67 in 2026; ex-R&D, modestly dilutive 2026-27, accretive from 2028.","Full control of anito-cel eliminates profit-sharing/royalty obligations; accelerates development and commercial launch.","Arcellx becomes wholly owned subsidiary of Gilead; ACLX common stock to be delisted from Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115361,"accession_number":"0001104659-26-018314","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Gilead to acquire Arcellx for $115/share plus $5 CVR; implied equity value $7.8B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["$115 per share cash at closing plus one contingent value right of $5 per share; total implied equity value ~$7.8B.","CVR pays $5 if cumulative worldwide sales of anito-cel exceed $6B by Dec 31, 2029.","FDA accepted BLA for anito-cel in relapsed/refractory multiple myeloma; PDUFA date Dec 23, 2026.","Transaction expected to close Q2 2026; requires majority tender, regulatory approvals, and customary conditions.","Gilead currently owns ~11.5% of Arcellx; deal builds on existing Kite collaboration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115360,"accession_number":"0000882095-26-000003","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gilead Q4/FY2025: revenue up 5% to $7.9B Q4, full-year EPS $6.78; guides 2026 sales $29.6-30B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP diluted EPS $1.74 vs $1.42 YoY; non-GAAP diluted EPS $1.86 vs $1.90.","Q4 product sales up 5% to $7.9B; HIV sales up 6% to $5.8B; Biktarvy $4.0B (+5%).","Full year 2025 total revenues $29.4B (+2%); product sales ex-Veklury $28.0B (+4%).","Full year GAAP diluted EPS $6.78 vs $0.38; non-GAAP $8.15 vs $4.62.","FY2026 guidance: product sales $29.6-30B, non-GAAP diluted EPS $8.45-8.85."],"consensus_eps_estimate":null,"consensus_eps_actual":6.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":29443000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131767,"accession_number":"0001104659-25-113968","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Gilead Sciences EVP & General Counsel Deborah Telman to depart Dec 5, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Deborah H. Telman will step down as EVP, Corporate Affairs and General Counsel effective December 5, 2025.","Her employment with Gilead will terminate later in December.","No successor or interim arrangement has been announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131766,"accession_number":"0000882095-25-000044","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gilead Q3 2025: Non-GAAP EPS $2.47 beats $2.02; product sales ex-Veklury up 4% to $7.1B; guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $2.43 vs $1.00; non-GAAP EPS $2.47 vs $2.02; revenue $7.8B up 3% YoY.","Biktarvy sales up 6% to $3.7B; Descovy up 20% to $701M; HIV portfolio up 4% to $5.3B.","Veklury down 60% to $277M; Cell therapy down 11% to $432M; Trodelvy up 7% to $357M.","Full-year product sales guidance raised to $28.4-28.7B; non-GAAP EPS raised to $8.05-8.25.","Operating cash flow $4.1B; dividends $1.0B; share repurchases $435M in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":5.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":21518000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131765,"accession_number":"0000882095-25-000041","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Gilead settles Biktarvy patent litigations; no generic entry expected before April 1, 2036","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlements with Lupin, Cipla, and Laurus Labs resolve patent disputes over generic Biktarvy.","No generic version of Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) permitted in US before April 1, 2036.","Agreements are subject to standard acceleration provisions.","Biktarvy is Gilead's leading HIV treatment; extending exclusivity protects significant revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148360,"accession_number":"0000882095-25-000035","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Gilead names Erin Burkhart as SVP, Controllership and principal accounting officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Erin Burkhart, formerly Group VP and CAO at BioMarin, appointed effective September 22, 2025.","Burkhart succeeds Diane E. Wilfong, who steps down as interim Controller and principal accounting officer on the same date.","Burkhart previously held accounting/finance roles at Eli Lilly and began career at Arthur Andersen and Deloitte."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148359,"accession_number":"0000882095-25-000030","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gilead Q2: revenue $7.1B, Biktarvy +9%, product sales ex-Veklury +4%; FY guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $7.1B (+2% YoY), product sales ex-Veklury $6.9B (+4%); Biktarvy $3.5B (+9%).","GAAP diluted EPS $1.56 vs $1.29 YoY; non-GAAP diluted EPS $2.01, flat YoY.","FY2025 guidance raised: product sales $28.3-28.7B, diluted EPS $5.85-6.15, non-GAAP EPS $7.95-8.25.","HIV sales +7% to $5.1B; Trodelvy +14% to $364M; Cell therapy -7% to $485M.","FDA approved Yeztugo as first twice-yearly HIV prevention; MYR impairment $190M."],"consensus_eps_estimate":null,"consensus_eps_actual":2.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":13749000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148358,"accession_number":"0000882095-25-000022","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Gilead amends bylaws to revise advance notice, proxy rules, and governance provisions","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Revised advance notice requirements for director nominations and stockholder proposals, including enhanced disclosure and universal proxy compliance.","Reserved white proxy card for exclusive use of the company; updates majority vote and board vacancy provisions.","Conformed stockholder meeting notice and list provisions to recent Delaware General Corporation Law amendments.","Added emergency governance provisions under DGCL Section 110; other clarifying and administrative changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167135,"accession_number":"0000882095-25-000015","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Gilead annual meeting: all directors elected, say-on-pay approved, 4 proposals defeated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected; CEO Daniel P. O'Day received 953.6M votes for (93.8% support).","Advisory say-on-pay approved with 929.6M for votes, ~90.9% of cast excluding broker non-votes.","Ratification of Ernst & Young as auditor for 2025 passed with 1.04B votes for (93.0%).","Four stockholder proposals (CEO pay ratio factor, independent chair, human rights policy, DEI contractor risks) all defeated.","Broker non-votes accounted for ~100M shares on director elections and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167134,"accession_number":"0000882095-25-000009","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gilead Q1 revenue flat at $6.7B; GAAP EPS $1.04 vs -$3.34; cuts GAAP EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $6.7B unchanged YoY; product sales ex-Veklury up 4% to $6.3B.","GAAP diluted EPS $1.04 vs $(3.34) in Q1 2024; non-GAAP diluted EPS $1.81 vs $(1.32).","Biktarvy sales $3.1B (+7% YoY); HIV product sales up 6% to $4.6B.","Full-year GAAP diluted EPS guidance cut to $5.65-$6.05 from $5.95-$6.35; product sales unchanged.","Cash $7.9B; operating cash flow $1.8B; $1.0B dividends, $730M buyback in Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":6667000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184496,"accession_number":"0001104659-25-023012","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Gilead CAO Sandra Patterson departs; Diane Wilfong appointed interim CAO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sandra Patterson, SVP, Corporate Controller and CAO, is leaving the company.","Diane E. Wilfong appointed interim Corporate Controller and CAO, effective March 12, 2025.","Wilfong previously served as Gilead's Corporate Controller and CAO from Feb 2016 to Mar 2023.","Wilfong, 63, also held similar roles at Computer Sciences Corp, Caesars Entertainment, and Eastman Kodak.","Company will conduct a search for a permanent successor; no departure reason provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184495,"accession_number":"0000882095-25-000003","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gilead Q4 revenue up 6% to $7.6B; full year EPS hit by $4.2B impairment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 product sales ex-Veklury +13% to $7.2B; HIV sales +16% to $5.5B, Biktarvy +21% to $3.8B.","Full year 2024 diluted EPS $0.38 vs $4.50, reflecting $4.2B Immunomedics IPR&D impairment and $3.9B CymaBay charge.","Non-GAAP diluted EPS Q4 $1.90 (+10%); full year $4.62 vs $6.72; cash, equivalents & securities $10.0B.","FY2025 guidance: product sales $28.2-28.6B; non-GAAP EPS $7.70-8.10; Veklury sales expected $1.4B.","Issued $3.5B senior notes in Q4; paid $973M dividends and repurchased $350M stock."],"consensus_eps_estimate":null,"consensus_eps_actual":0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":28754000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201082,"accession_number":"0001104659-24-128088","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K/A","filed_at":"2024-12-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Gilead appoints Dietmar Berger as Chief Medical Officer effective Jan 2, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dietmar Berger, MD PhD, will become Chief Medical Officer and member of senior leadership team on January 2, 2025.","Berger succeeds Merdad Parsey, MD PhD, who will stay as Senior Advisor through Q1 2025.","Berger previously served as Chief Medical Officer and Global Head of Development at Sanofi.","Berger will oversee Gilead's virology, oncology, inflammation portfolio and global Development/Medical Affairs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201084,"accession_number":"0001104659-24-121025","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Gilead issues $3.5B in senior notes across four tranches with maturities 2029-2064","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $750M 4.80% Senior Notes due 2029, $1B 5.10% due 2035, $1B 5.50% due 2054, $750M 5.60% due 2064.","Net proceeds to be used for general corporate purposes, including possible repayment of indebtedness.","Underwriting agreement with Barclays Capital Inc. and BofA Securities, Inc. dated November 13, 2024.","Notes sold under existing shelf registration statement; supplemental indenture entered November 20, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201083,"accession_number":"0000882095-24-000025","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gilead Q3 revenue up 7% to $7.5B; raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $1.00 (down from $1.73) due to $1.75B Immunomedics IPR&D impairment; Non-GAAP EPS $2.02 vs $2.29.","Biktarvy sales $3.5B (+13% YoY); HIV product sales $5.1B (+9%); Trodelvy $332M (+17%).","Full-year product sales guidance raised to $27.8-28.1B (from $27.1-27.5B); Non-GAAP EPS raised to $4.25-4.45 from $3.60-3.90.","Operating cash flow $4.3B in Q3; paid $983M dividends and repurchased $300M stock.","Oncology sales $816M (+6%); Cell therapy sales $485M flat YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":21185000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217105,"accession_number":"0000882095-24-000020","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gilead Q2 revenue $7.0B (+5%), Non-GAAP EPS $2.01; raised Non-GAAP FY guidance to $3.60-$3.90","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 revenue $7.0B (+5% YoY); GAAP diluted EPS $1.29 (prior $0.83), Non-GAAP diluted EPS $2.01 (prior $1.34).","HIV sales +3% to $4.7B; Biktarvy sales +8% to $3.2B; Oncology +15% to $841M; Trodelvy +23% to $320M.","Full-year 2024 product sales guidance unchanged at $27.1-27.5B; non-GAAP EPS guidance raised to $3.60-$3.90; GAAP EPS lowered to $0.00-$0.30.","Phase 3 lenacapavir for HIV prevention showed 100% efficacy in cisgender women; CymaBay acquisition closed for $3.9B.","Product gross margin 77.7% GAAP, 86.0% non-GAAP; operating cash flow $1.3B after $1.2B transition tax payment."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":13640000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217104,"accession_number":"0001104659-24-080355","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Gilead CMO Merdad Parsey to depart early 2025; successor search begins","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chief Medical Officer Merdad Parsey, M.D., Ph.D., will leave Gilead early next year.","Parsey will remain CMO until Q1 2025 to assist with transition while successor is identified.","He joined Gilead in November 2019 and oversaw expansion of pipeline to 54 ongoing clinical trials.","CEO Daniel O'Day praised Parsey's role in doubling the portfolio and advancing virology, oncology, and inflammation.","No formal departure date; transition expected through Q1 2025 or as mutually agreed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236870,"accession_number":"0000882095-24-000016","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Gilead stockholders approve officer exculpation amendment, elect directors, pass say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Officer exculpation amendment approved with 905.5M for, 101.7M against (85.6% support).","All nine director nominees elected; CEO Daniel O'Day received 939.1M for, 63.1M against.","Advisory say-on-pay passed with 928.7M for, 78.6M against (91.7% of votes cast).","Ernst & Young ratified as auditor with 1.04B for, 74.1M against.","Three stockholder proposals (employee board seat, abortion risk report, equity retention) all defeated by wide margins."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236869,"accession_number":"0000882095-24-000010","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gilead Q1 GAAP loss per share $(3.34) on $3.9B CymaBay charge; guidance slashed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS loss $(3.34) vs $0.80 YoY; non-GAAP loss $(1.32) vs $1.37.","Revenue up 5% to $6.7B; base business ex-Veklury up 6% to $6.1B.","Biktarvy up 10% to $2.9B; Oncology up 18% to $789M.","Full-year GAAP EPS guidance cut to $0.10–$0.50 from $5.15–$5.55; non-GAAP to $3.45–$3.85 from $6.85–$7.25.","Cash $4.7B; operating cash flow $2.2B; dividends paid $990M; $400M stock buyback."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":6686000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254481,"accession_number":"0001104659-24-037619","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["7.01","9.01","8.01"],"status":"ready","headline":"Gilead completes $4.3B acquisition of CymaBay; seladelpar added to liver pipeline","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total equity value ~$4.3 billion; Gilead paid $32.50 per CymaBay share.","Tender offer resulted in 77.3% of shares tendered (93.7M shares); remaining shares converted at same price.","CymaBay becomes wholly owned subsidiary; CBAY to be delisted from Nasdaq on March 22, 2024.","Transaction expected to reduce Gilead's 2024 GAAP/non-GAAP EPS by $3.10-$3.20; including costs, $3.35-$3.45 relative to prior guidance.","Seladelpar (for primary biliary cholangitis) is key asset; safety/efficacy not yet established."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254480,"accession_number":"0001104659-24-034493","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Gilead director Kevin Lofton to retire at May 8, 2024 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kevin E. Lofton notified the Board of his retirement effective at the conclusion of his term at the 2024 annual meeting on May 8.","Decision not a result of any disagreement with the Board or management.","No replacement or new director appointment announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254479,"accession_number":"0000950103-24-002027","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2024-02-12T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Gilead to acquire CymaBay for $4.3B, adding seladelpar for PBC with FDA priority review","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Gilead to pay $32.50/share in cash, total equity value of $4.3 billion, a 27% premium over CymaBay's Feb 9 close.","Seladelpar (PPARδ agonist) for primary biliary cholangitis has FDA priority review; PDUFA date Aug 14, 2024.","Phase 3 RESPONSE trial: seladelpar achieved primary composite endpoint (61.7% biochemical response vs 20% placebo).","Deal expected to close in Q1 2024, subject to HSR clearance and majority tender; termination fee of $151.6M.","Upon FDA approval, transaction expected to be ~neutral to Gilead EPS in 2025 and significantly accretive thereafter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254478,"accession_number":"0000882095-24-000003","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gilead Q4 revenue $7.1B (-4% YoY); FY23 non-GAAP EPS $6.72; guides FY24 product sales $27.1-27.5B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 GAAP EPS $1.14 (down from $1.30); non-GAAP EPS $1.72 (up from $1.67).","Full-year 2023 product sales $26.9B, flat YoY; HIV sales up 6% to $18.2B; Biktarvy up 14% to $11.8B.","Oncology sales up 37% for full year; Cell Therapy $1.9B (+28%); Trodelvy $1.1B (+56%).","Veklury sales fell 44% to $2.2B in FY23; Q4 Veklury $720M (-28% YoY).","FY24 guidance: product sales $27.1-27.5B, Veklury ~$1.3B, GAAP EPS $5.15-5.55, non-GAAP EPS $6.85-7.25."],"consensus_eps_estimate":null,"consensus_eps_actual":4.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":27116000000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254477,"accession_number":"0001104659-24-010051","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Gilead appoints Ted Love, MD, to Board of Directors; board expands to 10","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Love elected to Board effective February 1, 2024; board size increased from 9 to 10.","He will serve on Audit Committee beginning after 2024 Annual Meeting, subject to reelection.","Dr. Love is former CEO of Global Blood Therapeutics and current chair of BIO board.","He also serves on boards of Royalty Pharma and Structure Therapeutics.","No arrangement or related-party transactions exist in connection with his appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271947,"accession_number":"0000882095-23-000029","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gilead Q3 2023: EPS beats on lower tax; raises full-year product sales guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $7.1B flat YoY; product sales ex-Veklury up 5% to $6.4B.","GAAP diluted EPS $1.73 vs $1.42 YoY; non-GAAP diluted EPS $2.29 vs $1.90.","Biktarvy sales grew 12% to $3.1B; Oncology sales up 33% to $769M.","Full-year product sales guidance raised to $26.7-26.9B; non-GAAP EPS raised to $6.65-6.85.","Veklury sales fell 31% to $636M; R&D expenses rose to $1.5B on clinical activity and magrolimab discontinuations."],"consensus_eps_estimate":null,"consensus_eps_actual":3.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":20002000000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288807,"accession_number":"0001104659-23-100638","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2023-09-14T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Gilead issues $2B in senior notes: $1B at 5.25% due 2033, $1B at 5.55% due 2053","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $1,000,000,000 aggregate principal of 5.250% Senior Notes due 2033.","Issued $1,000,000,000 aggregate principal of 5.550% Senior Notes due 2053.","Net proceeds will be used for general corporate purposes.","Underwriting agreement entered with Barclays Capital Inc. and Citigroup Global Markets Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288806,"accession_number":"0001104659-23-092665","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2023-08-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Gilead reports EVOKE-02 Phase 2 data: SG+Pembro 56% ORR in 1L mNSCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORR 69% in PD-L1 TPS≥50% (Cohort A), 44% in <50% (Cohort B); overall ORR 56%.","Median DOR not reached; 6-month DOR rate 88% in both cohorts.","Any-grade TEAEs 100%, Grade≥3 70%; 1 treatment-related death (sepsis).","Data inadvertently posted early by IASLC; Gilead discloses via 8-K.","Phase 3 EVOKE-03 comparing SG+Pembro vs Pembro monotherapy is ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288805,"accession_number":"0000882095-23-000022","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gilead Q2 revenue $6.6B (+5%); EPS down to $0.83 on $525M legal charge; guidance raised ex-Veklury","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total product sales ex-Veklury up 11% to $6.3B; HIV sales up 9% to $4.6B, Biktarvy up 17% to $3.0B.","Oncology sales up 38% to $728M; Trodelvy up 63% to $260M, Cell Therapy up 27% to $469M.","GAAP diluted EPS $0.83 vs $0.91 YoY; non-GAAP EPS $1.34 vs $1.58; impact of $0.32 from $525M HIV antitrust litigation accrual.","Full-year 2023 guidance: total product sales raised to $26.3-26.7B (prev $26.0-26.5B); ex-Veklury raised to $24.6-25.0B; Veklury lowered to ~$1.7B (prev ~$2.0B).","GAAP EPS guidance lowered to $4.50-4.85 (prev $4.75-5.15); non-GAAP EPS lowered to $6.45-6.80 (prev $6.60-7.00)."],"consensus_eps_estimate":null,"consensus_eps_actual":1.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":12951000000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309477,"accession_number":"0000882095-23-000019","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2023-05-05T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Gilead stockholders approve director slate, ESPP amendments; three shareholder proposals defeated","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees elected with majority support; highest vote for Bluestone (995.9M for), lowest for Lofton (925.9M for).","Ernst & Young ratified as auditor for FY2023 with 1,047M for vs 63.8M against.","Say-on-pay passed with 919.1M for (92.0% of votes cast); future votes set to annual.","ESPP amendments approved (996.9M for) authorizing additional 25M shares, plan extended to 2033.","Three stockholder proposals defeated: proxy access nominee (7.4M for), special meeting rights (46.4M for), patent exclusivity report (165.4M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309476,"accession_number":"0000882095-23-000014","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2023-04-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gilead Q1: ex-Veklury product sales +15% to $5.7B; lowers GAAP EPS guidance to $4.75-$5.15","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 total revenue $6.4B (-4% YoY); product sales ex-Veklury up 15% to $5.7B.","HIV sales $4.2B (+13%); Biktarvy sales $2.7B (+24%); Oncology sales $670M (+59%).","Non-GAAP diluted EPS $1.37 vs $2.12 YoY; GAAP EPS $0.80 vs $0.02.","GAAP EPS guidance lowered to $4.75-$5.15 from $5.30-$5.70; non-GAAP unchanged $6.60-$7.00.","Cash & equivalents $7.2B; paid $969M dividends, repurchased $400M stock in Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":6352000000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328199,"accession_number":"0001104659-23-011167","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2023-02-06T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Gilead reduces special-meeting ownership threshold to 15% from 20%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board amended bylaws to lower ownership threshold for calling a special meeting to 15% of outstanding common stock.","Previous threshold was 20%; change effective February 6, 2023.","One or more stockholders in aggregate must hold at least 15% to call a special meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328198,"accession_number":"0000882095-23-000003","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2023-02-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gilead Q4 2022 rev $7.4B, EPS $1.30; ex-Veklury sales +9%; FY 2023 guidance $26.0-26.5B product sales","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $7.4B (+2%); product sales ex-Veklury +9% to $6.3B.","GAAP diluted EPS Q4 $1.30 vs $0.30; non-GAAP $1.67 vs $0.69.","FY 2022 Biktarvy sales $10.4B (+20%); Trodelvy $680M (+79%); Cell Therapy $1.5B (+68%).","FY 2023 guidance: product sales $26.0-26.5B; GAAP EPS $5.30-5.70; non-GAAP EPS $6.60-7.00.","Q4 operating cash flow $2.6B; dividends $916M; share repurchases $791M."],"consensus_eps_estimate":null,"consensus_eps_actual":3.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":27281000000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345852,"accession_number":"0000882095-22-000022","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2022-10-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gilead Q3 revenue $7.0B, EPS $1.42; raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $7.0B (-5% YoY); core product sales ex-Veklury up 11% to $6.1B.","GAAP diluted EPS $1.42 (vs $2.05); Non-GAAP EPS $1.90 (vs $2.65).","Biktarvy sales +22% to $2.8B; oncology sales +79% to $578M; Veklury -52% to $925M.","Raises 2022 guidance: product sales $25.9-$26.2B, Non-GAAP EPS $6.95-$7.15.","Acquired IPR&D $448M, including $389M for MiroBio; operating CF $2.9B in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":2.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":19892000000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362271,"accession_number":"0001104659-22-099101","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2022-09-12T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Gilead settles patent litigation for Descovy, Vemlidy, Odefsey; generic licenses begin 2031-2032","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreements with Lupin, Apotex, Macleods, Hetero, Cipla resolve patent challenges for HIV drugs.","License for Descovy and Vemlidy begins Oct 31, 2031; for Odefsey begins Jan 31, 2032, with earlier entry possible.","Agreements filed with FTC and DOJ; dismissals filed in Delaware district court.","Settlement removes litigation uncertainty but establishes generic entry timeline for key HIV portfolio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362270,"accession_number":"0000882095-22-000016","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2022-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gilead Q2 revenue $6.3B, EPS $0.91; raises FY product sales and non-GAAP EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $6.3B (+1% YoY); GAAP EPS $0.91 (down from $1.21); non-GAAP EPS $1.58 (down 13%).","Biktarvy sales $2.6B (+28% YoY); oncology sales $527M (+71% YoY) driven by cell therapy and Trodelvy.","HIV product sales $4.2B (+7% YoY); HCV sales $448M (-18% YoY); Veklury sales $445M (-46% YoY).","FY guidance raised: product sales $24.5-25.0B (prev $23.8-24.3B); non-GAAP EPS $6.35-6.75 (prev $6.20-6.70).","Operating cash flow $1.8B in Q2; cash & equivalents $7.0B as of June 30, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":0.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":12850000000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362269,"accession_number":"0001104659-22-083642","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2022-07-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Gilead Sciences names Sandra Patterson as new CAO, replacing Diane Wilfong","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Diane Wilfong to step down as SVP, Corporate Controller and CAO effective March 1, 2023.","Sandra Patterson, current VP, Assistant Controller, appointed as successor CAO effective March 1, 2023.","Wilfong will remain post-transition to support strategic initiatives.","Patterson has 11 years at Gilead; prior roles at Arthur Andersen, Raychem, PeopleSoft/Oracle, Clorox.","No financial impact, guidance changes, or other material events reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381800,"accession_number":"0001104659-22-066521","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2022-05-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Gilead EVP and General Counsel Brett Pletcher to retire, shift to part-time","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pletcher will retire as EVP, Corporate Affairs and General Counsel, transitioning to part-time to support successor and litigation.","Base salary and 2022 bonus will be pro-rated based on part-time schedule; no 2023 bonus or long-term incentives.","Arrangement approved by Compensation and Talent Committee on May 25, 2022.","Pletcher will advise on ongoing litigation matters during part-time service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381799,"accession_number":"0001104659-22-056435","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Gilead shareholders approve 2022 Equity Incentive Plan, elect directors, reject most proposals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected 9 directors; CEO O'Day received 871.8M votes for (87.2%) and 71.4M against.","Ratified Ernst & Young as auditor for FY2022: 1.02B for, 60.6M against.","Advisory approval of executive compensation: 875.8M for, 74.4M against, 2.2M abstentions.","Approved 2022 Equity Incentive Plan authorizing up to 132M shares: 864.6M for, 85.9M against.","Shareholder proposal for special meeting with 10% threshold passed (52.2% for); independent chair, labor rep, lobbying review, anticompetitive oversight proposals failed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381798,"accession_number":"0000882095-22-000010","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2022-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gilead Q1 revenue $6.6B (+3%), non-GAAP EPS $2.12 (+4%), GAAP EPS $0.02 due to $2.7B impairment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.02 vs $1.37 Q1 2021 due to $2.7B IPR&D impairment; non-GAAP EPS $2.12, +4% YoY.","Biktarvy sales $2.2B (+18%), oncology sales $420M (+60%) led by Trodelvy $146M (+103%) and cell therapy $274M (+43%).","Veklury sales $1.5B (+5%); HIV total $3.7B (+2%); HCV sales $399M (-22%).","Updated GAAP EPS guidance to $3.00-$3.50 from $4.70-$5.20; non-GAAP EPS and revenue guidance unchanged.","Cash $6.8B; operating cash flow $1.8B includes $1.25B legal settlement; $725M Arcus opt-in payment, $352M buybacks."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":6590000000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399772,"accession_number":"0001104659-22-030888","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2022-03-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Gilead's Trodelvy meets Phase 3 endpoint in HR+/HER2- metastatic breast cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TROPiCS-02 met primary endpoint: statistically significant PFS improvement vs physician's choice chemo in 543 patients.","First interim OS analysis showed numerical improvement but not statistically significant; final OS readout expected in 2024.","Safety profile consistent with prior studies; no new safety concerns observed.","Gilead reaffirms 2022 guidance; oncology revenue goal of 1/3 by 2030 unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399771,"accession_number":"0001104659-22-010300","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2022-02-01T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Gilead settles Biktarvy patent litigation with ViiV for $1.25B upfront + 3% royalty through 2027","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["One-time payment of $1.25B to ViiV in Q1 2022; pre-tax charge of $1.25B recorded in Q4 2021.","Ongoing 3% royalty on U.S. sales of Biktarvy and bictegravir products until October 5, 2027.","Settlement resolves all pending and potential claims across U.S. and international jurisdictions.","ViiV grants Gilead a broad worldwide license and covenant not to sue for bictegravir."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399770,"accession_number":"0000882095-22-000003","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2022-02-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gilead Q4 GAAP EPS $0.30, revenue $7.2B (-2% YoY); 2022 guidance $23.8-24.3B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.30 vs $1.23 YoY; non-GAAP $0.69 vs $2.19 (includes $1.25B legal charge)","Q4 product sales $7.2B (-2% YoY); ex-Veklury up 8% to $5.8B","Biktarvy sales up 22% YoY to $4.5B; Cell Therapy up 47% to $239M","2022 guidance: product sales $23.8-24.3B; GAAP EPS $4.70-5.20; non-GAAP EPS $6.20-6.70","Cash flow: $3.2B operating; debt repayment $1B; dividends $894M; cash $7.8B at Dec 31"],"consensus_eps_estimate":null,"consensus_eps_actual":4.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":27305000000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399769,"accession_number":"0001104659-22-001923","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2022-01-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Gilead announces retirement of EVP, General Counsel Brett Pletcher; transition by summer 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brett Pletcher plans to retire as EVP, Corporate Affairs, General Counsel and Corporate Secretary.","No formal retirement date set; he will continue in role while successor is identified.","Transition expected by end of summer 2022; Pletcher to assist in the process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418751,"accession_number":"0000882095-21-000024","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2021-10-28T23:59:59+00:00","items":["2.02","9.01","8.01"],"status":"ready","headline":"Gilead Q3 GAAP EPS $2.05, revenue $7.4B; Biktarvy record $2.3B; raises FY guidance; redeems $1B notes","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $2.05 vs $0.29 YoY; non-GAAP diluted EPS $2.65 vs $2.11 YoY.","Total Q3 revenue $7.4B (+13% YoY); product sales ex-Veklury $5.4B (-3% YoY).","Biktarvy sales record $2.3B (+20% YoY); Veklury sales $1.9B.","FY 2021 guidance raised: total product sales $26.0-26.3B; non-GAAP EPS $7.90-8.10.","Called $1B of 2023 notes (Floating Rate and 0.750% Senior Notes) for redemption on Nov 8, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":4.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":20061000000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436348,"accession_number":"0000882095-21-000018","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2021-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gilead Q2 2021 revenue $6.2B (+21% YoY); GAAP EPS $1.21, non-GAAP EPS $1.87; raises Veklury guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q2 revenue $6.2B (+21% YoY); product sales ex-Veklury $5.3B (+5%).","GAAP diluted EPS $1.21 (vs. loss of $2.66); non-GAAP diluted EPS $1.87 (+68%).","Veklury sales $829M; HIV sales $3.9B (-2%); Biktarvy up 24%; HCV up 23%.","FY2021 guidance: product sales $24.4-25.0B; Veklury $2.7-3.1B (prev $2.0-3.0B); non-GAAP EPS $6.90-7.25.","Quarterly dividend $0.71 payable Sep 29, record Sep 15; pipeline updates include lenacapavir NDA filing."],"consensus_eps_estimate":null,"consensus_eps_actual":2.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":12640000000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-07-29T23:59:59+00:00|436348"}